本文選題：大株紅景天注射液　切入點(diǎn)：普羅布考　出處：《河北醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:探究與分析大株紅景天聯(lián)合普羅布考治療腦梗死的臨床療效及對相關(guān)因素的影響。方法:選取廊坊市人民醫(yī)院自2015年3月至2015年12月收治的腦梗死患者120例,采取隨機(jī)數(shù)字表法分為A、B、C三組,每組各40例,三組患者均給予健康教育、飲食指導(dǎo)、適量運(yùn)動,平穩(wěn)控制基礎(chǔ)疾病等治療,在保證治療質(zhì)量的前提下,A組給予常規(guī)治療:包括抗血小板聚集、降血脂、降血壓、降血糖、擴(kuò)張冠狀動脈等治療,并酌情使用脫水劑。B組給予常規(guī)治療+大株紅景天注射液。C組給予常規(guī)治療+大株紅景天注射液+普羅布考。觀察指標(biāo)包括:(1)治療前后腦梗死患者美國國立衛(wèi)生研究院卒中量表(National Institute of Health stroke scale,NIHSS)、日常生活能力指數(shù)評估量表(Barthel Index,BI)、改良Rankin量表(Modified Rankin Scale,MRS)、吞咽功能障礙分級量表(洼田飲水試驗(yàn)分級)、簡易精神狀態(tài)檢查表(Minimum Mental State Examination,MMSE)變化。(2)治療前后頸動脈斑塊的大小、厚度變化。(3)血脂指標(biāo):總膽固醇(total cholesterol,TC)、甘油三脂(Triglyceride,TG)、高密度脂蛋白(high density lipoprotein,HDL)、低密度脂蛋白(low densith lipoprotein,LDL)變化。(4)C反應(yīng)蛋白(C-reactive protein,CRP)、擴(kuò)血管物質(zhì)降鈣素基因相關(guān)肽(Calcitonin gene-related peptide,CGRP)、同型半胱氨酸(homocystine,Hcy)變化。(5)肝腎功能、心功能、心肌酶變化及心電圖變化。并通過SPSS19.0進(jìn)行統(tǒng)計(jì),所得到的結(jié)果再利用t進(jìn)行檢驗(yàn),對每個(gè)變量之間所存在的差異進(jìn)行統(tǒng)計(jì),觀察有無統(tǒng)計(jì)學(xué)意義?結(jié)果:三組治療后與治療前相比NHISS評分、MRS評分均顯著降低,BI指數(shù)、洼田飲水試驗(yàn)分級、MMSE評分均顯著增高,頸動脈斑塊大小、厚度均減小,TC、TG及LDL-C均降低,HDL-C升高,C組治療后與B組治療后、CRP、CGRP及Hcy均降低,差異有統(tǒng)計(jì)學(xué)意義。與A組治療后相比,B、C組治療后NHISS評分、MRS評分均顯著降低,BI指數(shù)、洼田飲水試驗(yàn)分級、MMSE評分均顯著增高,頸動脈斑塊大小、厚度均減小,TC、TG及LDL-C均降低,HDL-C升高,CRP、CGRP及Hcy均降低,差異有統(tǒng)計(jì)學(xué)意義。C組治療后與A、B組治療后相比NHISS評分、MRS評分均顯著降低,BI指數(shù)、洼田飲水試驗(yàn)分級、MMSE評分均顯著增高,頸動脈斑塊大小、厚度均減小,TC、TG及LDL-C均降低,HDL-C升高,CRP、CGRP及Hcy均降低,差異有統(tǒng)計(jì)學(xué)意義,(P0.05)。三組患者行肝、腎功能、心功能、心肌酶變化及心電圖變化等檢查均未見異常。結(jié)論:大株紅景天聯(lián)合普羅布考治療腦梗死的臨床療效突出,可明顯緩解病情,改善異常指標(biāo),安全有效。
[Abstract]:Objective: to investigate and analyze the clinical effect of Rhizoma Rhodiola and Probucol in the treatment of cerebral infarction. Methods: 120 patients with cerebral infarction treated in Langfang people's Hospital from March 2015 to December 2015 were selected. Patients in each group were given health education, diet guidance, moderate exercise, stable control of basic diseases, and so on, and were divided into three groups with 40 cases in each group by random digital table method, and the patients in each group were treated with health education, diet guidance, moderate exercise, stable control of basic diseases, and so on. Under the premise of ensuring the quality of treatment, group A was given routine treatment, including antiplatelet aggregation, lowering blood lipid, lowering blood pressure, lowering blood sugar, dilating coronary artery, etc. As appropriate, group B was given routine treatment with large strain of Rhodiola injection. C group was given routine treatment of probucol injection of large strain Rhodiola injection. The observed indexes include: 1) National Health of patients with Cerebral Infarction before and after treatment. The National Institute of Health stroke scale, the activity of Daily living Index (ADL), the modified Rankin scale (modified Rankin scale), the dysphagia scale (Wadi Water Test scale), the Minimum Mental State examination scale (MMSE), the modified Rankin scale (modified Rankin scale), the National Institute of Health stroke scale (NIH), the modified Rankin scale (modified Rankin scale), the modified Rankin scale (modified Rankin scale), the modified Rankin scale (modified Rankin scale), the scale of dysphagia, the Minimum Mental State examination scale (MMSE). (2) carotid plaque size before and after treatment, Changes in blood lipids: total cholesterol cholesterol total cholesterol cholesterol total TCN, triglyceride-triglyceride TGG, high density lipoprotein high density protein HDLX, low density lipoprotein low densith lipoprotein change. C-reactive CRPN, calcitonin gene-related gene-related gene-related, homocysteine (HDL4), C-reactive protein (C-reactive protein), calcitonin gene-related peptidea (calcitonin gene-related peptidet), changes in serum lipids and blood lipids: total cholesterol: total cholesterol: total cholesterol; triglyceride; High density lipoprotein; low density lipoprotein; low density lipoprotein; C-reactive protein; calcitonin gene-related peptide; calcitonin gene-related gene-related; Hcy5) liver and kidney function, Cardiac function, myocardial enzyme changes and electrocardiogram changes. And through SPSS19.0 statistics, the results obtained by t test, the differences between each variable for statistical observation, there is no statistical significance? Results: after treatment, the NHISS scores and Mrs scores in the three groups were significantly lower than those before treatment, and the scores of Wata drinking water test were significantly higher than those before treatment, and the carotid plaque size was significantly increased. The thickness of TG and LDL-C decreased significantly after treatment in group C and group B, the NHISS scores and Mrs scores in group C were significantly lower than those in group A, and the scores of NHISS and Mrs in group C were significantly lower than those in group B after treatment, and there was a significant difference between group C and group B after treatment, and the scores of NHISS and Mrs in group C were significantly lower than those in group A, and the scores of NHISS and Mrs in group C were significantly lower than those in group A. The scores of MMSE were significantly increased, carotid plaque size and thickness were decreased, HDL-C was increased and Hcy and CGRP were decreased. The difference was statistically significant. The NHISS scores and Mrs scores in group C were significantly lower than those in group A B after treatment. The scores of NHISS scores and carotid plaques were significantly higher in group C than in group B, and the scores of Wadi drinking water test were significantly higher than those in group A and B, and the size of carotid plaques was significantly increased in group C. The thickness of TG and LDL-C were all decreased, HDL-C was increased, CGRP and Hcy were decreased, the difference was statistically significant (P 0.05). The three groups were given liver, renal function and cardiac function. Conclusion: the clinical effect of RDRC combined with Probucol in the treatment of cerebral infarction is obvious, which can obviously alleviate the condition, improve the abnormal index, and be safe and effective.
【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R743.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 許云鶴;劉永剛;趙小妹;董輝;;丁苯酞注射液治療急性腦梗死的療效及對血清sTRAIL OPG TNF-α的影響[J];中國實(shí)用神經(jīng)疾病雜志;2016年13期

2 周芬芬;;缺血性腦卒中發(fā)生早期神經(jīng)功能惡化(END)的相關(guān)因素分析[J];中國實(shí)用神經(jīng)疾病雜志;2015年03期

3 祝臘香;龐洪波;;非瓣膜性心房顫動患者缺血性腦卒中的危險(xiǎn)因素分析[J];中國實(shí)用神經(jīng)疾病雜志;2015年01期

4 季向紅;;丁苯酞軟膠囊合銀杏葉注射液治療急性腦梗死23例臨床觀察[J];中醫(yī)藥導(dǎo)報(bào);2014年16期

5 唐立鴻;康勁;薛玉梅;;高尿酸血癥與缺血性腦卒中的相關(guān)研究進(jìn)展[J];中華老年心腦血管病雜志;2014年08期

6 錢怡寧;王擁軍;劉改芬;潘岳松;;低高密度脂蛋白膽固醇血癥對缺血性腦卒中患者一年預(yù)后的影響[J];中華老年心腦血管病雜志;2014年07期

7 龐越;;阿司匹林聯(lián)合氯吡格雷治療急性腦梗死臨床觀察[J];中國現(xiàn)代藥物應(yīng)用;2014年13期

8 趙久晗;商秀麗;;高齡缺血性腦卒中患者危險(xiǎn)因素及臨床預(yù)后[J];中國老年學(xué)雜志;2014年12期

9 武U，

本文編號：1669492